Adagene (ADAG) Competitors $2.24 -0.10 (-4.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.26 +0.02 (+0.89%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. FULC, CGEM, KMDA, INBX, AURA, ADCT, PRTC, YMAB, AUTL, and MBXShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), Kamada (KMDA), Inhibrx Biosciences (INBX), Aura Biosciences (AURA), ADC Therapeutics (ADCT), PureTech Health (PRTC), Y-mAbs Therapeutics (YMAB), Autolus Therapeutics (AUTL), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Fulcrum Therapeutics Cullinan Therapeutics Kamada Inhibrx Biosciences Aura Biosciences ADC Therapeutics PureTech Health Y-mAbs Therapeutics Autolus Therapeutics MBX Biosciences Adagene (NASDAQ:ADAG) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Do insiders and institutionals hold more shares of ADAG or FULC? 9.5% of Adagene shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts prefer ADAG or FULC? Adagene currently has a consensus target price of $7.00, indicating a potential upside of 212.50%. Fulcrum Therapeutics has a consensus target price of $9.60, indicating a potential upside of 37.14%. Given Adagene's higher possible upside, equities analysts plainly believe Adagene is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Fulcrum Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, ADAG or FULC? Fulcrum Therapeutics has lower revenue, but higher earnings than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$103.20K1,022.96-$33.42MN/AN/AFulcrum TherapeuticsN/AN/A-$9.73M-$1.22-5.74 Does the media refer more to ADAG or FULC? In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 2 mentions for Adagene. Fulcrum Therapeutics' average media sentiment score of 1.44 beat Adagene's score of 1.30 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Adagene Positive Fulcrum Therapeutics Positive Is ADAG or FULC more profitable? Adagene's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Fulcrum Therapeutics N/A -31.05%-28.96% Which has more risk & volatility, ADAG or FULC? Adagene has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. SummaryFulcrum Therapeutics beats Adagene on 6 of the 11 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.57M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.4375.4125.98Price / Sales1,022.96429.44514.54181.13Price / CashN/A46.6837.5660.44Price / Book1.969.6112.156.29Net Income-$33.42M-$53.29M$3.29B$271.07M7 Day Performance1.82%0.13%0.74%3.87%1 Month Performance35.76%5.61%4.81%4.88%1 Year Performance-35.82%10.49%60.57%26.12% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene3.4348 of 5 stars$2.24-4.3%$7.00+212.5%-26.3%$105.57M$103.20K0.00260Short Interest ↓Gap UpFULCFulcrum Therapeutics2.6257 of 5 stars$7.27-5.1%$7.57+4.1%+103.5%$414.34M$80M-5.96100News CoveragePositive NewsShort Interest ↓CGEMCullinan Therapeutics2.2064 of 5 stars$6.84-2.1%$26.80+291.8%-62.9%$412.93MN/A-2.1230News CoverageAnalyst ForecastKMDAKamada4.4699 of 5 stars$7.22+1.1%$13.00+80.1%+29.5%$410.59M$169.52M21.24360Positive NewsShort Interest ↓INBXInhibrx Biosciences1.2961 of 5 stars$29.10+3.3%N/A+82.5%$408.20M$200K-2.75166News CoveragePositive NewsAURAAura Biosciences2.2576 of 5 stars$6.47-0.2%$22.00+240.0%-36.9%$402.54MN/A-3.3050ADCTADC Therapeutics3.0352 of 5 stars$3.51-0.8%$7.75+120.6%+13.2%$398.25M$70.84M-2.24310News CoverageShort Interest ↓PRTCPureTech Health0.5572 of 5 stars$16.42+1.2%N/A-21.2%$391.71M$6.17M0.00100Short Interest ↑Gap DownYMABY-mAbs Therapeutics2.0846 of 5 stars$8.59+0.1%$9.62+12.0%-35.1%$389.86M$87.68M-17.18150News CoveragePositive NewsAUTLAutolus Therapeutics3.9156 of 5 stars$1.43-2.1%$9.12+537.8%-65.1%$388.57M$10.12M-1.70330Positive NewsShort Interest ↓MBXMBX Biosciences0.1435 of 5 stars$10.90-5.6%N/AN/A$388.01MN/A-2.40N/ANews CoverageAnalyst Upgrade Related Companies and Tools Related Companies FULC Competitors CGEM Competitors KMDA Competitors INBX Competitors AURA Competitors ADCT Competitors PRTC Competitors YMAB Competitors AUTL Competitors MBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAG Stock Alerts